<DOC>
	<DOCNO>NCT00779740</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , parallel group comparison study verify clinical equivalency old formulation ( 50 mcg mometasone furoate [ MF ] 50 μL solution per spray ) new formulation ( 50 mcg MF 100 μL solution per spray ) patient perennial allergic rhinitis .</brief_summary>
	<brief_title>Equivalency Study Two Formulations Mometasone Furoate Nasal Spray ( Study P04419 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients mongoloid race reside Japan satisfy follow criterion : Patients symptoms perennial allergic rhinitis moderate severe degree , accord classification severity guideline treatment nasal allergy ( partial revision ) well score least 4 score 4 nasal symptom , time obtain informed consent pretreatment observation period . Patients positive skin reaction test specific IgE antibody quantitation , positive cytological examination nasal discharge ( eosinophil ) nasal challenge test . Outpatients least 16 year age time inform consent obtain . Male female . Patients ability give write informed consent ( informed consent guardian must also obtain patient young 20 year ) . Patients keep nasal allergy diary without fail . Patients coexist tuberculous disease lower respiratory tract infection , patient , time registration , acute upper respiratory tract infection , acute pharyngitis , acute amygdalitis etc . Patients coexist infection systemic mycosis effective antibiotic . Patients unhealed nasal septum ulcer , nasal surgery scar , nasal trauma . Patients history hypersensitivity steroids mometasone furoate . Patients pregnant nursing may pregnant patient patient ' partner desire become pregnant study period . Patients severe hepatic , renal , cardiac , hematological disease , diabetes mellitus , hypertension serious coexisting disease whose general condition poor . Patients also allergic pollen pollen release season occur study period . Patients vasomotor rhinitis eosinophilic rhinitis . Patients nasal condition may interfere efficacy evaluation investigational product . Patients develop disease affect nasal symptom pretreatment observation period , i.e. , 7 day actual registration . Patients participate participate clinical trial another investigational drug within 120 day ( 4 month ) day inform consent study . Patients period discontinuation previous treatment effective allergic rhinitis start investigational product administration sufficient avoid use . Patients receive specific desensitization therapy nonspecific modulation therapy discontinue therapy within 90 day ( 3 month ) provide consent study ( unless therapy ongoing maintenance therapy start 180 day [ 6 month ] consent study ) . Other patient judge inappropriate study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>